Alvogen Expands Development and Commercialization Collaboration with Pfenex for PF708 in EU- MENA and ROW
Shots:
- Pfenex to receive $2.5M as upfront and milestones for EU & MENA- milestones for ROW & 60% profit split on sales. Alvogen’s subsidiary Theramex & SAJA to get rights to develop and commercialize in EU- Switzerland & MENA respectively (Ex-Mainland China- Hong Kong- Singapore- Malaysia and Thailand) undisclosed in ROW
- On 11 Jun-2018 Pfenex & Alvogen collaborated for the development and commercialization of Pfenex’s PF708 in the US
- Pfenex’s PF708 (teriparatide- biosimilar) is evaluated in P-III study for patients with osteoporosis and is expected to be approved by the US FDA in Q4’19
Ref: Pfenex | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com